SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Resilient Biotics is utilizing advanced microbiome genomics and data science for prevention and precision treatment of deadly infectious diseases.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.